Chemspace | Drug Candidate Analogs. “JNJ-63576253”

Warning!
Your browser does not support JavaScript or JavaScript support is disabled.
Display of the content may be incorrect. Please make sure that JavaScript is enabled in your browser. Warning!
Apparently you are using proxy server to access this site.
It means that display of the content may be incorrect.

Warning!
Your browser does not support HTML5.
Display of the content may be incorrect. Please make sure that your browser supports HTML5 syntax.

Home News Drug Candidate Analogs. “JNJ-63576253”

8 March 2021

Drug Candidate Analogs. “JNJ-63576253”

This January, the article 'Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)' describing lead optimization process of a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations was published.

The result of this led JNJ-63576253 (also known as TRC-253) to a clinical stage as a next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC).

Drug candidate JNJ-63576253 contains 6-sulfanylidene-5,7-diazaspiro[3.4]octan-8-one moiety in its backbone.

We have made a set of compounds, which have such parts – the perfect start for your research!

Drug Candidate Analogs. “JNJ-63576253”

Enquire for x () from in

Enquire for

Would you like to submit a custom request?

Enquiry for a list of compounds

Please select the ship to country:

Sign in